Opicapone in Uk Clinical Practice: effectiveness, Safety and Cost Analysis in Patients With Parkinson’s Disease

References

• Fox SH , KatzenschlagerR, LimSYet al. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov. Disord., 33(8), 1248–1266 (2018).
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence . Parkinson’s disease in adults: diagnosis and management (2022). https://www.nice.org.uk/guidance/ng71/evidence/full-guideline-pdf-4538466253
   Google Scholar
• Lane EL . L-DOPA for Parkinson’s disease – a bittersweet pill. Eur. J. Neurosci., 49(3), 384–398 (2019).
   PubMed Web of Science ®Google Scholar
• Muller T , MohrJD. Long-term management of Parkinson’s disease using levodopa combinations. Expert. Opin. Pharmacother., 19(9), 1003–1011 (2018).
   PubMed Web of Science ®Google Scholar
• Almeida L , RochaJF, FalcaoAet al. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clin. Pharmacokinet., 52(2), 139–151 (2013).
   PubMed Web of Science ®Google Scholar
• Kiss LE , FerreiraHS, TorraoLet al. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J. Med. Chem., 53(8), 3396–3411 (2010).
   PubMed Web of Science ®Google Scholar
• Montioli R , VoltattorniCB, BertoldiM. Parkinson’s disease: recent updates in the identification of human dopa decarboxylase inhibitors. Curr. Drug. Metab., 17(5), 513–518 (2016).
   PubMed Web of Science ®Google Scholar
• Fabbri M , FerreiraJJ, LeesAet al. Opicapone for the treatment of Parkinson’s disease: a review of a new licensed medicine. Mov. Disord., 33(10), 1528–1539 (2018).
   PubMed Web of Science ®Google Scholar
• Scott LJ . Opicapone: a review in Parkinson’s disease. CNS Drugs, 35(1), 121–131 (2021).
   PubMed Web of Science ®Google Scholar
• Ferreira JJ , LeesA, RochaJFet al. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol., 15(2), 154–165 (2016).
   PubMed Web of Science ®Google Scholar
• Lees AJ , FerreiraJ, RascolOet al. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol., 74(2), 197–206 (2017).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency . Ongentys, INN-opicapone. Summary of product characteristics (2022). https://www.ema.europa.eu/en/documents/product-information/ongentys-epar-product-information_en.pdf
   Google Scholar
• U.S. Food and Drug Administration . ONGENTYS (opicapone) prescribing information (2022). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212489s000lbl.pdf
   Google Scholar
• Australian Government Department of Health and Therapeutic Goods . Australian public assessment report for opicapone (2022). https://www.tga.gov.au/sites/default/files/auspar-opicapone-210210.docx
   Google Scholar
• U.S. Food and Drug Administration . Submitting documents using real-world data and real-world evidence to FDA for drugs and biologics guidance for industry (2022). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-documents-using-real-world-data-and-real-world-evidence-fda-drugs-and-biologics-guidance
   Google Scholar
• Cave A , KurzX, ArlettP. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin. Pharmacol. Ther., 106(1), 36–39 (2019).
   PubMed Web of Science ®Google Scholar
• Reichmann H , LeesA, RochaJFet al. Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study. Transl. Neurodegener., 9(1), 9 (2020).
   PubMed Web of Science ®Google Scholar
• Stacy M , HauserR, OertelWet al. End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin. Neuropharmacol., 29(6), 312–321 (2006).
   PubMed Web of Science ®Google Scholar
• Fahn S (Ed.), EltonR. Unified Parkinson’s Disease Rating Scale. In: Recent Developments in Parkinson’s Disease (Volume 2).MarsdenCD, CalneDB, GoldsteinM ( Eds). MacMillan Healthcare Information, NJ, USA, 153–164 (1987).
   Google Scholar
• Jenkinson C , FitzpatrickR, PetoV, GreenhalfR, HymanN. The PDQ-8: development and validation of a short-form Parkinson’s disease questionnaire. Psychol. Health., 12, 805–814 (1997).
   Web of Science ®Google Scholar
• Chaudhuri KR , Martinez-MartinP, BrownRGet al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov. Disord., 22(13), 1901–1911 (2007).
   PubMed Web of Science ®Google Scholar
• Beecham J , KnappM. Costing psychiatric interventions. In: Measuring Mental Health Needs.ThornicroftG ( Ed.). Gaskell, London, UK, 200–224 (2001).
   Google Scholar
• Mccrone P , PayanCA, KnappMet al. The economic costs of progressive supranuclear palsy and multiple system atrophy in France, Germany and the United Kingdom. PLoS ONE, 6(9), e24369 (2011).
   PubMed Web of Science ®Google Scholar
• Busse M , Al-MadfaiDH, KenkreJ, LandwehrmeyerGB, BentivoglioA, RosserA. Utilisation of healthcare and associated services in Huntington’s disease: a data mining study. PLoS Curr., 3, RRN1206 (2011).
   PubMedGoogle Scholar
• Mccrone P , HeslinM, KnappM, BullP, ThompsonA. Multiple sclerosis in the UK: service use, costs, quality of life and disability. Pharmacoeconomics, 26(10), 847–860 (2008).
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR , SchapiraAH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol., 8(5), 464–474 (2009).
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR , YatesL, Martinez-MartinP. The non-motor symptom complex of Parkinson’s disease: a comprehensive assessment is essential. Curr. Neurol. Neurosci. Rep., 5(4), 275–283 (2005).
   PubMedGoogle Scholar
• Rivest J , BarclayCL, SuchowerskyO. COMT inhibitors in Parkinson’s disease. Can. J. Neurol. Sci., 26(Suppl. 2), S34–S38 (1999).
   PubMed Web of Science ®Google Scholar
• Lees A , FerreiraJJ, RochaJFet al. Safety profile of opicapone in the management of Parkinson’s disease. J. Parkinsons Dis., 9(4), 733–740 (2019).
   PubMedGoogle Scholar
• Greenwood J , PhamH, ReyJ. Opicapone: a third generation COMT inhibitor. Clin. Park. Relat. Disord., 4, 100083 (2021).
   PubMedGoogle Scholar
• Economic, social and financial cost of Parkinson’s on individuals, carers and their families in the UK: final report (2022). https://www.shu.ac.uk/research/specialisms/health-and-social-care-research/reports/economic-social-and-financial-cost-of-parkinsons-on-individuals-carers-and-their-families
   Google Scholar
• Andlin-Sobocki P , JonssonB, WittchenHU, OlesenJ. Cost of disorders of the brain in Europe. Eur. J. Neurol., 12(Suppl. 1), S1–S27 (2005).
   PubMed Web of Science ®Google Scholar
• Gumber A . Effects of out-of-pocket (OOP) payments and financial distress on quality of life (QoL) of people with Parkinson’s (PwP) and their carers. Health Qual. Life Outcomes, 15(Suppl. 1), A33 (2017).
   PubMedGoogle Scholar
• Findley LJ , WoodE, LowinJ, RoederC, BergmanA, SchifflersM. The economic burden of advanced Parkinson’s disease: an analysis of a UK patient dataset. J. Med. Econ., 14(1), 130–139 (2011).
   PubMedGoogle Scholar
• Weir S , SamnalievM, KuoTCet al. Short- and long-term cost and utilization of health care resources in Parkinson’s disease in the UK. Mov. Disord., 33(6), 974–981 (2018).
   PubMed Web of Science ®Google Scholar
• Leta V , Van WamelenDJ, SauerbierAet al. Opicapone and levodopa-carbidopa intestinal gel infusion: the way forward towards cost savings for healthcare systems? J. Parkinsons Dis., 10(4), 1535–1539 (2020).
   PubMedGoogle Scholar